PMV Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that PMV Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($21.06M) | Nov 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($21.21M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($21.21M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($17.44M) | May 9, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($17.44M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($17.44M) | Nov 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($19.23M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($1.21M) | Aug 7, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($1.21M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($15.27M) | May 9, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($15.27M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($15.27M) | Nov 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($16.64M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($17.44M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($17.44M) | Nov 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($19.13M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($19.13M) | Aug 8, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($19.13M) | Nov 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($18.23M) | Nov 9, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($17.31M) | Nov 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($22.52M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($22.88M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($21.56M) | May 9, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($21.89M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($20.17M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($18.22M) | May 9, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($19.63M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($20.12M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($21.48M) | May 9, 2024 |
| Q3 | 2023 | Mar 31, 2023 | ($21.48M) | May 10, 2023 |
| Q3 | 2023 | Sep 30, 2022 | ($19.38M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($17.89M) | Aug 9, 2023 |
| Q3 | 2023 | Mar 31, 2022 | ($18.62M) | May 10, 2023 |
| Q1 | 2022 | Mar 31, 2022 | ($18.62M) | May 10, 2022 |
| Q3 | 2022 | Sep 30, 2021 | ($15.10M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($13.05M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($11.67M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($8.70M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($8.09M) | Aug 13, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($7.65M) | May 14, 2021 |